Identification Of Biomarkers Of Response And Toxicity To Chemoradiotherapy For Oesophageal Tumours
Funder
National Health and Medical Research Council
Funding Amount
$496,935.00
Summary
Chemoradiotherapy for oesophageal tumours has high interpatient variability in response and toxicity to treatment. Predictive biomarkers of response and toxicity would help select patients who would benefit most from this treatment modality. The proposed project will determine blood-derived microRNA and mRNA profiles that identify patients according to risk of unfavourable treatment outcomes, enabling clinicians to offer personalised alternative treatment strategies for those patients.
Chemical And Structural Biology Validation Of Lamin B1 As A New Anti-cancer Target
Funder
National Health and Medical Research Council
Funding Amount
$638,272.00
Summary
The validation of new anti-cancer targets is critical for the development of new therapies. We have discovered a small molecule that disrupt the function Lamin B1 during cell division and decreases tumour growth significantly in vivo. With this research proposal, we will investigate the role that Lamin B1 exerts during cell division and why interfering with this protein has such a profound impact on cancer cells.
DOCetaxel With Or Without Radiation Therapy For Resectable Oesophageal Adenocarcinoma Based On Early PET Response To Induction Chemotherapy (DOCTOR).
Funder
National Health and Medical Research Council
Funding Amount
$1,024,738.00
Summary
Oesophageal cancer continues to have poor survival despite surgery. Patients responding to pre-operative chemotherapy have better survival than those who do not. This study proposes using early FDG-PET scan to identify patients not responding to standard chemotherapy. This will permit the timely change of therapy to alternative regimens with a newer agent with or without radiotherapy, aiming to improve outcomes. This represents a paradigm shift in the management of oesophageal cancer.
ALT-associated PML Bodies: Keys To The Biology And Treatment Of An Important Subset Of Cancers
Funder
National Health and Medical Research Council
Funding Amount
$813,614.00
Summary
Alternative Lengthening of Telomeres (ALT) is a molecular mechanism used by ~10% of cancers to sustain their relentless growth. ALT is common in sarcomas and brain tumours which are difficult to treat. ALT cancers contain nuclear structures called ALT-associated PML nuclear bodies (APBs) which may be part of the ALT machinery. This research will investigate characteristics of APBs and how they are formed, and will use this information to identify drugs to treat ALT tumours.
Identification Of Germline Variation That Predicts Progression Free Survival Following Chemotherapy For Advanced Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$633,156.00
Summary
Women diagnosed with ovarian cancer typically undergo surgery, followed by chemotherapy. However, the efficacy of chemotherapy varies widely, with some women responding well, whilst others are exposed to the toxic effects of a treatment that does them little good. We aim to identify the genes which explain why there are differences in response. This will lead to more individualised chemotherapy and improved outcomes for women with ovarian cancer.
Cyclotherapy: A New Approach To Stop The Side Effects Of Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$565,847.00
Summary
Cyto-toxic chemotherapy is a widely used treatment for cancer but is associated with significant side effects for the patient. These are due to the chemotherapy killing normal dividing cells in the gut, bone marrow and hair follicles. We will determine the potential of cyclotherapy in preventing these side effects. In cyclotherapy a pre-treatment temporarily stops normal cells from dividing and therefore protects them from the damage of subsequent chemotherapy.
Screening For Recently Defined Genetic Lesions In Poor Risk Adult And Childhood ALL, And Developing Treatment Approaches To Target Causative Pathways.
Funder
National Health and Medical Research Council
Funding Amount
$744,938.00
Summary
Most adults and 20% of children with ALL relapse and die of their disease. Chromosomal changes resulting in the formation of new proteins have been recently identified in a significant number of cases. Importantly, drugs targeting these proteins are in clinical practice for other diseases. We will develop new tests to rapidly identify these patients at diagnosis, and assess the efficacy of adding these drugs to first line treatment in a clinical trial. The outcome for these patients will likely ....Most adults and 20% of children with ALL relapse and die of their disease. Chromosomal changes resulting in the formation of new proteins have been recently identified in a significant number of cases. Importantly, drugs targeting these proteins are in clinical practice for other diseases. We will develop new tests to rapidly identify these patients at diagnosis, and assess the efficacy of adding these drugs to first line treatment in a clinical trial. The outcome for these patients will likely improve significantly using this approachRead moreRead less
Prevention Of Drug Toxicities With Dichloroacetic Acid - The Implications For Cancer Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$539,839.00
Summary
Many valuable cancer drugs have limited clinical use because of their toxic side effects. Our experiments with a new anti cancer drug called dichloroacetic acid (DCA) will determine if it can reduce the toxic effects of Cisplatin on the kidney and the effects of Doxorubicin on the heart.
The Oligoadenylate-RNAseL Pathway May Provide A Specific And Low Toxicity Approach To Therapy For Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$439,314.00
Summary
We have discovered that a pathway used to fight viral infections can be triggered to produce massive cell death in the mammary gland. We hope to be able to trigger this response in breast cancers through the strategic combination of available drugs. If successful this project will establish a new therapeutic strategy for breast cancer.
Interplay Between Metabolic Reprogramming And Oncogenic Signalling In The Cellular Response To Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$654,035.00
Summary
Chemotherapy resistance is a major barrier to the treatment of triple-negative breast cancer (TNBC). We seek to uncover an intimate link between cell metabolism and oncogenic signalling pathways in regulating the cellular response to chemotherapy. Our studies will identify a critical mechanism limiting the therapeutic efficacy of chemotherapy and investigate combination therapy strategies that could improve the treatment of TNBC.